Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immix Biopharma, Inc. - Common Stock (NQ: IMMX ) 2.100 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 2.100 Bid (Size) 2.080 (1) Ask (Size) 2.330 (1) Prev. Close 2.100 Today's Range 2.100 - 2.100 52wk Range 1.260 - 7.125 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis December 19, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis December 16, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Performance YTD -65.35% -65.35% 1 Month +27.27% +27.27% 3 Month +32.08% +32.08% 6 Month -1.41% -1.41% 1 Year -69.74% -69.74% More News Read More Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 December 10, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media December 09, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients November 25, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 October 02, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board September 19, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 August 28, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 August 12, 2024 Via InvestorPlace Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 July 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum June 17, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 May 13, 2024 Via InvestorPlace Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma April 29, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma on Track to Dose NXC-201 Patients in United States April 18, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 April 02, 2024 Via InvestorPlace Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial March 20, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative March 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering February 09, 2024 Via Investor Brand Network Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock February 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis February 07, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Proposed Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 25, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 25, 2024 Via Benzinga Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products January 24, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
